July 2009
VoSoL HC Otic Solution, a widely recognized brand of ear drops for the treatment of external ear infections has been added to ECR Pharmaceuticals' product line. VoSoL HC is prescribed frequently for what is commonly referred to as Swimmer's Ear, an acutely painful condition of the external ear canal caused by infections which may result from water getting into the ear. Distribution and promotion of VoSoL HC by ECR's sales organization will begin immediately. The prescription product is available in pharmacies nationwide.

^top of page

April 2009
ECR Pharmaceuticals introduced its new DexPak 6 Day TaperPak at the beginning of the second quarter and launched the product at its annual sales meeting. DexPak 6 Day offers health care professionals a new option in short term corticosteroid therapy. Physicians prescribe oral steroids for a variety of conditions including contact dermatitis, allergic disorders, and a wide range of inflammatory related symptoms. Compliance is critical for patients receiving oral corticosteroid therapy in order to assure prompt and continuing relief, as well as avoiding potential side effects. The TaperPak enhances patient compliance through providing twice daily dosing in an easy to follow format. DexPak 6 Day TaperPak offers notable benefits and competes in the very large packaged oral corticosteroid marketplace. Distribution and promotion of the product will begin immediately.

^top of page

March 2009
ECR Pharmaceuticals' Annual Sales Meeting was held in San Antonio, Texas and was highlighted by the launch of its new DexPak 6 Day TaperPak, an extension of the firm's established line of oral corticosteroid products. In addition to the various product related presentations and central to the purpose of the meeting was the announcement of the company's top sales performers during the previous 2008 calendar year.

This meeting also marked the first major gathering since Hi-Tech Pharmacal's acquisition of ECR. Hi-Tech provided its ECR employees with an excellent overview of its operations and the growth opportunities which will result from combining the organizations. (See Newsline, February, 2009)

^top of page

February 2009
Hi-Tech Pharmacal, an Amityville, NY publicly traded company on the NASDQ exchange, has acquired the privately held, Richmond, Virginia based ECR Pharmaceuticals. Hi-Tech is a major supplier of liquid, generic prescription products as well as branded OTC pharmaceuticals. The addition of a branded pharmaceutical arm provides new opportunities for the combined companies and enhanced synergy in respect to the development and acquisition of new products. For a more detail announcement of this transaction, please see the accompanying formal press release (News Release, March 2, 2009).

Hi-Tech Pharmacal Acquires ECR Pharmaceuticals AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 2, 2009--

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today the signing of a definitive agreement under which Hi-Tech acquired the assets of ECR Pharmaceuticals, a privately held branded specialty pharmaceutical company for $5.1 million in an all-cash transaction, which will be paid over an eight month period. Additionally, Hi-Tech may pay up to $4.0 million in performance incentives tied to future ECR product sales and profits. Under the terms of the acquisition Hi-Tech receives rights to ECR's product line, including branded prescription products for the treatment of allergy, headache and dermatitis/poison ivy. ECR Pharmaceuticals has 45 sales representatives promoting products to physicians and pharmacists in 12 mid-Atlantic and southern states. ECR had net sales of $13.2 million and operating income of $2.0 million in calendar 2008. The company will continue to operate under the name ECR Pharmaceuticals.

"This acquisition allows Hi-Tech to capitalize on ECR's growing sales, and brings experienced management with a successful track-record developing new products," said David Seltzer, President and CEO of Hi-Tech Pharmacal. "The addition of ECR makes Hi-Tech a more diverse and flexible company, as we have an additional outlet to market differentiated products currently in development. We believe that the ECR acquisition will be earnings accretive and cash flow positive in the near term, and contribute to the Company's long term growth."

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co., Inc.
William Peters, CFO, 631-789-8228

^top of page

November 2007
ECR recently announced that Cephalon, a major US pharmaceutical and biotech firm, had acquired the Company's marketing rights to Amrix, a once-a-day dosage muscle relaxant formulation. Amrix is the first in its class of once daily musculoskeletal relaxants. Its active ingredient is cyclobenzaprine, the most widely prescribed drug in this market.

ECR's VP, Pharmaceutical Operations, Davis Caskey, indicated that the sales potential for Amrix had grown markedly during its developmental period, and that the limited marketing exclusivity currently provided to newly developed formulations was the major factor in not promoting Amrix through its own sales group. "It would have been our preference to market the product through our own sales force and we had planned to do so. However, when a small company has spent 7 years and millions of dollars developing a product, and you have three years of exclusivity to try to recoup your expenses and make a profit, you have to be able to put significant resources into its marketing and do so quickly. We developed a product which we believe can offer patients significant therapeutic advantages, and at the end of the day the only reasonable decision was to place it with a company which could maximize its potential in the marketplace during the brief exclusivity period." Cephalon has more than 600 people in its sales force and is well established in the pain management market.

"It was a difficult decision for us because of the time and effort put into the product to achieve NDA approval. Small firms and their sales people don't often have the opportunity to promote a product with this potential, and the enthusiasm of our entire company was at its peak . But in balance, if you cannot maximize promotion of the product, physicians and healthcare professionals don't readily know about it, and patients don't benefit."

For more information about Amrix, please contact:
Cephalon Medical Services at usmedinfo@cephalon.com or toll free by calling 800-896-5855.

^top of page

March 2007
ECR has launched Lodrane 24D, a once-a- day antihistamine/decongestant formulation for the treatment of allergies, sinusitis, and nasal congestion. Lodrane 24D complements the firm's previously marketed Lodrane 24, a once daily dosed antihistamine formulation. Both Lodrane formulations contain brompheniramine, an alkylamine, which is among the most potent antihistamines. These products are available only by prescription.

Lodrane 24 and Lodrane 24D are both somewhat unique among the once-a-day antihistamine and antihistamine/decongestant products in that the dosage can be adjusted to match the patient's severity of symptoms or the level of allergens present (pollen, etc.). Initially, and during periods of more marked symptoms or higher pollen levels, patients may require two capsules, dosed once daily to achieve the desired relief. When symptoms lessen, the patient can lower the dose to one capsule daily. The latter benefits the patient by keeping a sufficient level of drug on board to continue to provide relief while also protecting against the reoccurrence of symptoms. This dosage format also has the additional benefits of being more cost effective while reducing the potential for possible side effects. Patients should consult their physician or pharmacist to discuss the best dosage format for them.

^top of page

March 2007
ECR Pharmaceuticals has received approval for its new drug application for AMRIX® (cyclobenzaprine hydrochloride extended release capsules). The product is a once-a-day dosage formulation and is indicated as an adjunct for the treatment of skeletal muscle spasm, notably that which is associated with back pain and similar musculoskeletal disorders. The product will be available only by prescription and the firm anticipates marketing the product by late summer 2007.

^top of page

March 2006
ECR has been a long-standing member of the Branded Pharmaceutical Association (BPA). The BPA is an organization of small to mid-sized pharmaceutical product distributors and manufacturers and serves as the "Voice for Specialty Pharma". The organization is comprised of approximately 40 firms which are located throughout the US. The BPA meets twice annually and its seminars range from regulatory and governmental updates, to presentations on improving performance. The organization serves as an active forum for keeping its membership advised of the continuing evolution of various state and federal programs and issues.

^top of page

October 2005
ECR Pharmaceuticals' Cornerstone Society, which honors the contributions of former employees and retirees of the company, has added two names to its list of recipients. Earlier this year, Robert Harvey and Harold Stone of the firm's distribution department elected to retire. Both men had previously worked for AH Robins and after their retirement from that firm had joined ECR. E. Claiborne Robins, Jr., President and CEO of ECR noted "that it was a real advantage to be able to secure individuals whose background allowed them to have an immediate impact on the operation of the company during its early years."

Mr. Stone joined ECR in 1991, the year the company was founded, and Mr. Harvey came on board in 2000 when Stone elected to assume part-time status. Their election to the firm's Cornerstone Society recognizes the notable contributions each made to the firm's initial development.

^top of page

November 2004
Product Utilizes Elite Pharmaceutical's Drug Delivery Technology
ECR Pharmaceuticals is pleased to announce that it has launched LODRANE 24® (brompheniramine maleate, modified release), the firm's new once-a-day allergy product. Lodrane 24 utilizes Elite Pharmaceutical, Inc.'s (AMEX:ELI) exclusive Msphere™ extended release technology to provide for once daily dosing. The once-a-day formulation is intended to enhance patient convenience and compliance for those who require chronic allergy therapy. The product will compete in the $3 billion dollar US allergy market. Lodrane 24 will be promoted to healthcare providers in the US by ECR Pharmaceuticals field sales representatives and will be available by prescription through pharmacies. Elite Pharmaceuticals will manufacture the product and will receive a royalty on product revenues.

E. Claiborne Robins, Jr., President and CEO of ECR Pharmaceuticals noted that Lodrane 24 offers healthcare providers and patients with a new alternative when treating perennial and seasonal allergies. "Our objective was to take an effective antihistamine with a proven track record, enhance its delivery, and thus improve patient therapy. We are pleased to have worked with Elite Laboratories to apply their drug delivery technology to our product, which has resulted in an improved dosage form."

Bernard Berk, President and CEO of Elite, commented, "We are excited about the launch of Lodrane 24 utilizing Elite's Msphere extended release technology. We look forward to continuing to build our working relationship with ECR Pharmaceuticals with respect to this allergy product and other products to be launched in the future."
November 15, 2004 Press Release Excerpt

^top of page

October 2004
ECR Pharmaceuticals is pleased to be a member of the Branded Pharmaceutical Association. The BPA represents small to mid-size pharmaceutical companies that market and manufacture brand name drug products. BPA members are dedicated to serving the consumer, the medical community, and the pharmaceutical industry with quality products and services. The association's mission is to promote the common interest of its members through conducting semi-annual meetings, making contacts with regulatory agencies regarding industry issues, and providing critical information to its member companies.

Most consumers are aware of what is often referred to as "Big Pharma" i.e. those major pharmaceutical firms which conduct the majority of the research for new molecular entities and hence play a vital role in developing new drug therapies. Likewise, most consumers are aware of the large generic drug industry which functions to make generic substitutes for drugs after patent expiration. However, many people have little awareness of the smaller branded pharmaceutical industry whose companies provide cost effective prescription and over the counter products to a very large segment of our population. Through innovation and efficient operation, these firms offer enhanced formulations and dosage forms which improve patient convenience and compliance.

^top of page

February 2004
At the firm's 2004 Annual Meeting, ECR Pharmaceuticals' President and CEO, E. Claiborne Robins, Jr. announced the formation of a new recognition award, The Cornerstone Society. This award honors key former employees and retirees from ECR whose contributions have played a major role in the development and success of the firm. The plaque, which will be on permanent display at the company's headquarters, is inscribed:

"Honoring the contributions of our former and retired employees
whose efforts have served as the foundation of our company".

In his remarks, Mr. Robins noted that a company's strength lies within its people and that in the development of a new firm, there are always those who lay the foundation and assure success for both the present and future. Mr. Robins indicated that it was with especially great pride to announce the first recipients of this recognition: Mr. Rudy L. Snow and Mr. Julian Rhine. Both men retired from the firm on March 31 after many years of outstanding service in ECR's field sales organization.

^top of page

Jean Scott

January 2011
ECR profiles an employee and his or her position so that others in the firm can gain a better understanding of this individual's responsibilities and contributions.

ECR Pharmaceuticals recognizes Jean Hill Scott, Administrative Assistant
in Pharmaceutical Administration.

*************************

Jean joined ECR's corporate administration in 2006. She came to ECR with extensive experience having worked for more than 10 years with a Richmond area security firm. Her responsibilities include assisting with the management of documents related to product development and on-going product requirements; as well as record keeping functions for products and physical properties. A recent new assignment has expanded Jean's responsibilities into record management for the company's field sales group.

Jean resides in Powhatan, Virginia and is an active member of her community association. Jean has two children, Sam and Mary. She is an avid gardener and enjoys painting and reading. We are pleased to recognize Jean Scott and her contributions to ECR Pharmaceuticals.

^top of page

March 2007
ECR profiles an employee and his or her position so that others in the firm can gain a better understanding of this individual's responsibilities and contributions.

ECR Pharmaceuticals recognizes Janice H. Hardin, Manager, Pharmaceutical Administration.

*************************

Janice Hardin joined ECR in 1991, only a few months after the founding of the company, and is one of its longest tenured employees. Janice has been involved in virtually all facets of the company during its growth and development over the several years. During her service, the firm has moved to four different sites, requiring not only substantial physical relocations but an equal amount of administrative tasks associated with registering each facility. Her contributions in accomplishing these transitions were extraordinary.

In her position as Manager, Pharmaceutical Administration, Janice's responsibilities include oversight of internal office staff, personnel functions for home office and field sales employees, shipping and receiving, and inventory acquisition. She is also the interface with various organizations with which ECR partners in the conduct of clinical work, product development, and manufacturing.

Janice Hardin attended the Braxton School and the University of Mary Washington. She resides in Richmond with her husband and two children.

We are pleased to recognize Janice and her many contributions to the development of the company.

ECR Pharmaceuticals recognizes Ms. Grisel Clark, Accounting Assistant/ Accounts Receivable Supervisor.

Grisel Clark is a graduate of Commonwealth College in Hampton, Virginia and manages ECR's accounting activities. Grisel came to our firm in 2003 with an established background in accounting, bringing experience from a variety of industries, including both wholesale and retail trade.

Grisel is a native of Cuba and became a U.S. citizen in 2004. She is fluent in both English and Spanish. Grisel and her family enjoy going to the beach, kayaking, and dining out. She has three children and is currently expecting her first grandchild. Grisel and her family live in Gloucester, Virginia.

We are pleased to recognize Grisel and her contributions to the company.

April 2005
ECR profiles an employee and his or her position so that others in the firm gain a better understanding of this individual’s responsibilities and contributions.

*************************

ECR Pharmaceuticals recognizes Ms. Phyllis I. Long, Administrator, Customer Relations and Sales Services.

Phyllis Long joined ECR in 2002 with an impressive resume of experience which combined customer service and administrative talents. And with the initials 'PIL' she was an obvious fit within the pharmaceutical industry. Interacting with pharmaceutical wholesalers to assure adequate distribution of ECR's products and the maintenance of appropriate inventory levels for retail pharmacies is a key function of Ms. Long's position. An associated function, the introduction and distribution of new products, is also central to her responsibilities. In addition, Phyllis administers the planning and implementation of the firm's medical meetings and conventions, and assists with the coordination of the company's sales meetings. Other responsibilities include oversight of commercial product shipments, management of Medicaid reporting, and coordination of product destructions. Ms. Long obviously performs a vital role within the firm and we are pleased to acknowledge her many contributions.

Phyllis and her family live in Goochland, Virginia. She and her husband Mark have three children, whose school and extracurricular activities keep each of them on the go. The family enjoys camping and trips to the beach, river and bay.

October 2004
ECR profiles an employee and his or her position so that others in the firm gain a better understanding of this individual’s responsibilities and contributions.

ECR Pharmaceuticals recognizes Ms. Ginny Perrin, the firm's Data Management Administrator.

*************************

Ginny Perrin completed eight years of service with ECR in April of 2004. When Ginny joined the company in 1996, ECR had only four pharmaceutical home office employees. She obviously had a variety of assignments and responsibilities during the firm's early years and its subsequent rapid growth and field sales expansion. During this period, a major element of the company's success was its ability to track its sales and product distribution so that it could both reward its sales staff appropriately and position the firm to accommodate future growth. As ECR expanded, the collection and management of data from both internal and external sources became an even more vital task. Ginny's expertise in effectively managing this function for the company was recognized in 2000 with her promotion to Data Management Administrator. Ms. Perrin's responsibilities include the collection, management, and distribution of sales data as well as regulatory reporting. Ginny also manages the company's web site and administers the creation and development of sales materials. Ginny is a graduate of Virginia Tech, with a degree in Merchandising and Design. She brought significant previous retail experience when joining ECR. Ginny and her husband enjoy escaping to their country home in nearby Goochland County, Virginia as well as taking frequent camping trips. We are pleased to recognize Ms. Perrin's many contributions to ECR.

Rudy L. Snow

Julian Rhine

April 2004
ECR profiles an employee and his or her position so that others in the firm gain a better understanding of this individual’s responsibilities and contributions.

ECR Pharmaceuticals recognizes two retiring employees whose efforts have contributed so greatly to the development, growth, and success of the company.

*************************

In 1992, ECR purchased MediPlex Pharmaceuticals of Greensboro, North Carolina. With this acquisition came two exceptional individuals with substantial pharmaceutical experience: Mr. Rudy L. Snow and Mr. Julian Rhine. Each of these men would play major roles in developing and expanding the firm's base in the Mid-Atlantic Division.

Rudy Snow was a principal in MediPlex and assumed the reins as the first manager of ECR's Mid-Atlantic Division. Rudy brought extensive sales and management experience to ECR having achieved record setting sales with two previous firms. Mr. Snow merged the ECR/MediPlex sales forces and recruited various new positions for the rapidly developing company. The Mid-Atlantic Division quickly became the firm's sales leader and it continues to maintain this position today. Mr. Snow is a three time Golden Circle winner, which recognizes the company's top sales performances. In 1996 Rudy also earned the company's top sales recognition, the Summit Award.

In recognizing Mr. Snow at its Annual Meeting, Davis Caskey, ECR Vice President, Pharmaceutical Operations, noted that "Rudy Snow always assured his success by never letting anybody work harder than he did, and that this is the legacy which Rudy leaves to each of us".

Julian Rhine was a representative for MediPlex in Columbia, South Carolina when the company was merged into ECR. Julian had joined that firm after an extensive career in pharmaceutical sales with Marion-Merrell Dow and its predecessor companies. Mr. Rhine has earned numerous awards over the years including the prestigious Salesman of the Year with Dow Pharmaceuticals. Julian's success continued with ECR, as he earned Golden Circle recognition on five occasions, the last being in 2003, his final full year with ECR. Mr. Rhine is also the recipient of the firm's E. Claiborne Robins Award, presented in honor of his outstanding service not only to ECR Pharmaceuticals, but to the pharmaceutical industry, health care professionals, and his community.

When asked about his tremendous achievements, Julian indicated that he had never found a short cut to hard work, and that a positive attitude and friendly smile always seemed to help. Jack Boswell, ECR Director, Sales, remarked that "Julian Rhine epitomizes the individual which all professional sales people should strive to be". In a salute to Mr. Rhine, attendees at the firm's annual meeting donned stickers which read "I Want To Be Like Julian".

Both of these gentlemen will retire from ECR Pharmaceuticals on March 31, 2004. Mr. Snow and Mr. Rhine were recently recognized by ECR's President, E. Claiborne Robins, Jr., as the initial honorees of the firm's newly created Cornerstone Society. This recognition honors the substantial contributions each made to the early growth and success of the firm.

All of the employees of ECR Pharmaceuticals want to convey our very best wishes to these truly outstanding individuals.

Robert Harvey

Harold Stone

January 2004
ECR profiles an employee and his or her position so that others in the firm gain a better understanding of this individual’s responsibilities and contributions.

*************************

The timely and efficient distribution of a pharmaceutical company's products is critical toward providing the level of service its customers need. We recognize the key members of our Distribution Group, Robert Harvey and Harold Stone.

Mr. Harvey came to ECR in March, 2000 following 30 years of service at AH Robins Company. His experience included positions in inventory control, production planning, and distribution center allocation. Robert is responsible for the distribution of ECR's commercial product to its wholesale and retail customers. He is a Richmond native and attended Richmond Public Schools and J. Sargent Reynolds Community College. Robert is an avid Washington Redskins' fan and enjoys traveling to FedEx field to see them play.

Harold Stone had 22 years of service at AH Robins prior to joining the newly developed E.C. Robins organization in 1990. Harold has worked in various capacities within the company and assumed ECR Pharmaceuticals' primary distribution function in 1992. Mr. Stone is currently responsible for distribution of supplies and samples to ECR's field sales organization as well as assisting with the distribution of commercial product. Harold is also an avid Redskins' fan and Nascar enthusiast and can be found at Richmond International Raceway on race days. He is also an excellent gardener and the fruit of his labor is enjoyed by the staff at ECR.

We are pleased to recognize these outstanding employees and extend our gratitude for their excellent service to our firm, its employees, and our customers.

October 2003
ECR profiles an employee and his or her position so that others in the firm gain a better understanding of this individual’s responsibilities and contributions.

*************************

We recognize Jackie Jackson of ECR's Customer Service Department.

Jackie joined ECR in 1998 and completed her five year anniversary with the firm in October. Ms. Jackson is responsible for our company's product order entry, sample and literature fulfillment, correspondence and mail. She also shares the responsibility for auditing product and samples distribution, as well as field personnel record keeping. As ECR's receptionist, Jackie is often the first face one will see or the first voice one will hear when contacting ECR. We congratulate Jackie for her many contributions and the enthusiasm she brings to our firm.

Jackie is a native of South Carolina and enjoys returning to her home state to visit family and the beach. She is married and has three children, each of which keeps her busy with various school and community activities.

^top of page